<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04645004</url>
  </required_header>
  <id_info>
    <org_study_id>20F.911</org_study_id>
    <nct_id>NCT04645004</nct_id>
  </id_info>
  <brief_title>Antenatal Platelet Response on Aspirin and Correlation With Hypertensive Disorders of Pregnancy: a Pharmacokinetic Study Through Pregnancy</brief_title>
  <acronym>APROACH-PK</acronym>
  <official_title>Impact of Maternal Aspirin Tehrapy on the Maternal/Fetal Unit at Delivery: a Study of Aspirin Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics Through Pregnancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>March of Dimes</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Longitudinal pharmacokinetic and pharmacodynamic study in first and third trimester of&#xD;
      pregnancy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a longitudinal addition to an existing R21cohort enrolled in the first trimester&#xD;
      to include a first and third trimester assessment of pharmacokinetics/pharmacodynamics&#xD;
      (PK/PD) of aspirin and how individual factors impact aspirin PK/PD in pregnancy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 29, 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>One arm PK/PD study of aspirin in pregnancy1</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>salicylic acid level</measure>
    <time_frame>24 hour</time_frame>
    <description>time/concentration profile</description>
  </primary_outcome>
  <primary_outcome>
    <measure>serum thromboxane</measure>
    <time_frame>1 week</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PFA-100</measure>
    <time_frame>1 week</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Preeclampsia</condition>
  <arm_group>
    <arm_group_label>Aspirin</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>81mg aspirin daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin 81Mg Ec Tab</intervention_name>
    <description>one tab daily</description>
    <arm_group_label>Aspirin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  &lt;16 weeks' gestational age&#xD;
&#xD;
          -  Singleton pregnancy&#xD;
&#xD;
          -  Plan to take 81mg aspirin due to high risk history (below), but not yet initiated&#xD;
&#xD;
          -  â‰¥1 risk factor:&#xD;
&#xD;
               -  Chronic hypertension&#xD;
&#xD;
               -  Type I or II diabetes&#xD;
&#xD;
               -  Previous preeclampsia&#xD;
&#xD;
               -  Renal disease&#xD;
&#xD;
               -  Autoimmune disease (SLE)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindication to aspirin&#xD;
&#xD;
          -  Current or planned use of any other anticoagulation&#xD;
&#xD;
          -  Current need for dialysis&#xD;
&#xD;
          -  Use of aspirin therapy prior to enrollment in the current pregnancy&#xD;
&#xD;
          -  Thrombocytopenia (&lt;150)&#xD;
&#xD;
          -  Other known platelet disorder/thrombophilia at enrollment&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Rupsa C Boelig, MD</last_name>
    <phone>215-955-9196</phone>
    <email>rupsa.boelig@jefferson.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Thomas Jefferson University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rupsa C Boelig, MD</last_name>
      <email>rupsa.boelig@jefferson.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 19, 2020</study_first_submitted>
  <study_first_submitted_qc>November 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 25, 2020</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pre-Eclampsia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Final results of this study will plan to be submitted for publication within 12 months of completion of analysis of samples. Following publication, a data set excluding any protected health information will be available on request pending agreement on use of data and appropriate IRB approval for data sharing agreement with the outside individuals or institutions requesting data. The data sharing agreement will provide that the individual/institution requesting the data will commit to using the data only for research purposes and not attempt to identify any individual participant, to secure the data using appropriate computer technology and security, and finally to destroy or return the data set after analyses are completed.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Following publication of data, 12 months following study completion</ipd_time_frame>
    <ipd_access_criteria>The data sharing agreement will provide that the individual/institution requesting the data will commit to using the data only for research purposes and not attempt to identify any individual participant, to secure the data using appropriate computer technology and security, and finally to destroy or return the data set after analyses are completed.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

